Advisory Committee Meetings; Amendment of Notice

Короткий зміст

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The meeting was announced in the Federal Register of October 20, 1995 (60 FR 54233). The amendment is being made to remove probucol, new drug application (NDA) 17-535 (Lorelco , Hoechst Marion Roussel) for a lipid altering indication from the agenda, and change the time schedule. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.